Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
CAMBRIDGE, Mass., Sept. 26, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cell & Gene Meeting on the Mesa at the Estancia La Jolla Hotel & Spa in La Jolla, CA on Wednesday, October 5, 2016 at 5:45pm Pacific time.
Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference organized specifically for the cell and gene therapy and regenerative medicine sector.
The presentation will be webcast live at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel‑T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel® and MACI® are registered trademarks of Vericel Corporation. ©2016 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
